Patients with inhibitors also have higher incidences of
mobility - related problems, hospitalizations, school and work absenteeism, and difficulty maintaining a job, along with higher treatment costs, compared with patients without inhibitors(Table1). As would be expected based on these factors, the QoL of patients with inhibitors is lower than for non-inhibitor hemophilia patients. A limited number of studies of psychosocial well-being have been performed in patients with hemophilia (reviewed by Cassis), and data exploring the specific issues faced by patients with inhibitors are largely lacking and highlight the need for more studies in this area.